Stephen Brozak


Caladrius Biosciences Inc Partnering Continues To Validate Its Immunotherapy Platform: WBB Securities

WBB Securities analyst Stephen Brozak came out today with a favorable report on Caladrius Biosciences Inc (NASDAQ:CLBS), after the company announced Tuesday that it has signed …

WBB Securities Raises Price Target For Sarepta Therapeutics Inc (SRPT) Ahead Of Eteplirsen FDA Decision

In a research report released today, WBB Securities analyst Stephen Brozak reiterated a Buy rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), and raised …

WBB Securities Raises Price Target for Celldex Therapeutics, Inc. Following Positive Phase II Results for Glioblastoma Vaccine Rintega

Celldex Therapeutics, Inc. (NASDAQ:CLDX) price target has been raised by research analyst Stephen Brozak at WBB Securities.

WBB Securities Raises Price Target For Sarepta Therapeutics Inc Following Positive Pre-NDA Meeting With FDA

Sarepta Therapeutics Inc (NASDAQ:SRPT) price target has been raised by research analyst Stephen Brozak at WBB Securities. The new price target now stands …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts